BPC-157 is a synthetic 15-amino-acid peptide modeled after a gastric protein and is being studied for tissue repair and GI support. It is not FDA-approved for human therapeutic use.

Human clinical data are limited. Long-term safety and standardized dosing are not established; use only under medical supervision.

Is BPC-157 allowed in sports?

BPC-157 may be prohibited by anti-doping organizations. Athletes must verify rules with their governing body before use.

How quickly might I see results?

GI-related benefits may be noticed in days to weeks; connective-tissue support can take several weeks and should be paired with rehab.

BPC-157: A Breakthrough Peptide for Healing, Recovery and Gut Health

Q: How does BPC-157 work?

Preclinical studies suggest support for angiogenesis, fibroblast activity, collagen remodeling, and inflammatory balance—mechanisms that may aid repair and gut integrity.

In the realm of advanced regenerative medicine and performance recovery, the peptide BPC-157 (Body Protection Compound-157) is gaining attention for its restorative power across tissues, joints and the gut. At Transformyou, we offer a medically supervised approach to peptide therapy — and in this overview you’ll learn what BPC-157 is, how it works, who may benefit, and why our clinical program ensures safe, effective use.

What is BPC-157?

BPC-157 is a synthetic fragment of a naturally occurring peptide found in human gastric juice, made up of 15 amino acids. It was identified for its cytoprotective and tissue-repair properties. Although research remains early, animal and lab-based studies show a remarkable ability to support healing of tendons, ligaments, muscle, nerves and gastrointestinal lining.

How does BPC-157 work?

While human trials are limited, mechanistic research suggests several pathways:

Promotes new blood-vessel formation (angiogenesis) and improved micro-circulation in injured tissue.
Stimulates fibroblast growth and migration, supporting collagen production, matrix repair and tissue rebuilding.
Modulates inflammatory responses and protects cells from oxidative damage, creating a favorable environment for repair.
Supports gastrointestinal membrane integrity, meaning it may provide benefits for gut health (ulcers, intestinal damage, “leaky gut”).
At Transformyou, we translate this science into a safe clinical plan — dosing, monitoring, supportive lifestyle/nutrition guidance and recovery-centric protocols.

Who is a candidate for therapy and what are the key outcomes?

People recovering from tendon, ligament, nerve or muscle injuries (sprains, overuse, surgical repair).
Individuals with persistent joint or soft-tissue pain where standard therapies stalled.
Those with gut concerns: chronic NSAID use, gastritis, ulcers, IBS/IBD and compromised gut integrity.
Performance-oriented individuals or practitioners of bio-optimization seeking accelerated recovery and tissue resilience.
Key outcomes we aim for:
Shorter downtime and improved structural healing in connective tissues.
Reduced pain, inflammation and improved functional recovery.
Enhanced gut lining repair, improved digestion and improved comfort.
Better overall tissue health — helping you move, recover and train (or live) at higher capacity.

How fast can you expect results, and how is it administered?

Some benefit may be seen within days to a week (especially gut repair) when combined with other supportive therapies.
More significant repair (tendons/ligaments) may take several weeks.
Administration methods vary: oral capsules, subcutaneous or intramuscular injections. Injection offers higher bioavailability; oral is preferred for gut applications.

What does the research say & what are the limitations?

The science is promising: numerous animal and in-vitro studies show BPC-157 improves tendon/ligament healing, protects the gut lining from damage, and supports nerve regeneration. Therefore, while BPC-157 offers exciting potential, it should be considered as part of a comprehensive recovery strategy, not a stand-alone cure.

Why Our Approach to BPC-157 is different

At Transformyou, we don’t simply offer the peptide — we integrate it into a broader optimization protocol:

Comprehensive assessment (injury history, gut health, recovery status, co-therapies).
Medical oversight with regular reviews, monitoring and integration into your recovery program.
High-quality sourcing: we only use U.S. licensed compounding pharmacies.
Lifestyle, nutrition and rehab support alongside peptide therapy — because healing is multi-factorial.
Transparent communication: we set realistic timelines, expectations and outcomes. You’ll know what to expect, when and why.

Whether you’re an athlete, recovering from injury or simply seeking advanced recovery support, our team is ready to guide you safely and strategically.

Ready to explore whether BPC-157 could be right for you? Contact us for a consultation — we’ll assess your goals, recovery profile and develop a tailored peptide-protocol plan.

Research:

Stable gastric pentadecapeptide BPC 157 is an antiulcer peptidergic agent, safe in inflammatory bowel disease clinical trials and wound healing, stable in human gastric juice and has no reported toxicity. Notably, it has a prominent effect on alcohol lesions (i.e., acute, chronic) and NSAIDs-lesions (interestingly, BPC 157 both prevents and reverses arthritis)… and acts as a free radical scavenger and exhibits neuroprotective properties.

(Sikiric, P., et al., Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. CPD, 2011. 17(16): p. 1612-1632.)

Molecules. 2014 Nov 19;19(11):19066-77. doi: 10.3390/molecules191119066. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Chang CH1, Tsai WC2, Hsu YH3, Pang JH4.

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Chung-Hsun Chang, Wen-Chung Tsai, Miao-Sui Lin, Ya-Hui Hsu, and Jong-Hwei Su Pang. 01 MAR 2011https://doi.org/10.1152/japplphysiol.00945.2010

Curr Pharm Des. 2013;19(1):76-83. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Sikiric P1, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Safic H, Suran J, Rak D, Dzidic S, Vrcic H, Sebecic B.

Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Danira Pevec, Tomislav Novinscak, Luka Brcic, Kristijan Sipos, Ivana Jukic, Mario Staresinic, Sandro Mise, Iva Brcic, Danijela Kolenc, Robert Klicek, Tihomir Banic, Marko Sever, Ana Kocijan, Lidija Berkopic, Bozo Radic, Gojko Buljat, Tomislav Anic, Ivan Zoricic, Ivan Bojanic, Sven Seiwerth, Predrag Sikiric. Med Sci Monit 2010; 16(3): BR81-88 ID: 878454 Published: 2010-02-26

Eur J Pharmacol. 1999 Aug 20;379(1):19-31. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Jelovac N1, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, Seiwerth S, Mise S, Turkovic B, Dodig G, Miklic P, Buljat G, Prkacin I

J Orthop Res. 2010 Sep;28(9):1155-61. doi: 10.1002/jor.21107. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Cerovecki T1, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P

J Orthop Res. 2006 May;24(5):1109-17. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Staresinic M1, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, Kokic N, Batelja L, Brcic L, Boban-Blagaic A, Zoric Z, Ivanovic D, Ajduk M, Sebecic B, Patrlj L, Sosa T, Buljat G, Anic T, Seiwerth S, Sikiric P

Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution? Predrag Sikiric, Sven Seiwerth, Rudolf Rucman, Domagoj Drmic, Mirjana Stupnisek, Antonio Kokot, Marko Sever, Ivan Zoricic, Zoran Zoricic, Lovorka Batelja, Tihomil Ziger, Kresimir Luetic, Josipa Vlainic, Zarko Rasic, Martina Lovric Bencic. Current Pharmaceutical Design. Volume 23 , Issue 27 , 2017

J Physiol Pharmacol. 2009 Dec;60 Suppl 7:191-6. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Brcic L1, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S

Regul Pept. 2010 Feb 25;160(1-3):33-41. doi: 10.1016/j.regpep.2009.11.005. Epub 2009 Nov 10. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Gjurasin M1, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, Kolenc D, Radic B, Seiwerth S, Sikiric P.

Curr Med Chem. 2012;19(1):126-32. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Sikiric P1, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Stambolija V, Zoricic Z, Vrcic H, Sebecic B.

Eur J Pharmacol. 2007 Sep 10;570(1-3):212-21. Epub 2007 Jun 16. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Tkalcević VI1, Cuzić S, Brajsa K, Mildner B, Bokulić A, Situm K, Perović D, Glojnarić I, Parnham MJ

Stable Gastric Pentadecapeptide BPC 157-NO-system Relation. Predrag Sikiric, Sven Seiwerth, Rudolf Rucman, Branko Turkovic, Dinko Stancic Rokotov, Luka Brcic,Marko Sever, Robert Klicek, Bozo Radic, Domagoj Drmic, Spomenko Ilic, Danijela Kolenc, Gorana Aralica, Mirjana Stupnisek, Jelena Suran, Ivan Barisic, Senka Dzidic, Hrvoje Vrcic, Bozidar Sebecic. Current Pharmaceutical Design. Volume 20 , Issue 7 , 2014

Regulatory Disclaimer (important):
The information provided here is for educational purposes only. BPC-157 is not approved by the FDA for therapeutic use in humans. Individual results may vary. This content does not constitute medical advice, diagnosis or treatment. Always consult your qualified healthcare provider before beginning any new therapy, especially peptides, and ensure it fits your medical profile.